Sun Pharmaceutical Share: Brokerages turn bullish post Organon deal, peg up to 16% upside; check latest target prices – Markets
Sun Pharmaceutical Organon Deal: Global and domestic nrokerages have turned increasingly constructive on Sun Pharmaceutical Industries following its announcement to acquire Organon & Co., citing the deal’s strategic fit, earnings accretion and strong cash‑flow profile. Several analysts have raised their target prices on the stock and now peg upside of up to 16 per cent…
